On July 3, Hansoh Pharmaceutical rose 4.41% in regular trading, trading at HKD 32.78/share, with turnover of HKD 161 million.
On the news front, the company announced on the evening of July 2 that its self-developed Class 1 new drug HS-20136-2 injection received two clinical trial approval notices from China's National Medical Products Administration (NMPA), for indications of Type 2 Diabetes Mellitus and Weight Management respectively. This marks the latest in a series of pipeline catalysts, following the NDA acceptance of weight-loss drug olatorepatide and HS-10568 injection, as well as the drug registration certificate granted for pemosareptide injection.
Meanwhile, the broader pharmaceutical sector strengthened collectively, with Luye Pharma up 5.38%, CSPC Pharma up 3.84%, and China Biologic up 3.46%. Multiple institutions maintain Buy ratings on Hansoh Pharmaceutical with target prices ranging from HKD 40 to HKD 46.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
